|HEALTH CARE PROFESSIONAL |
February 3-6, 2015
Hilton Hawaiian Village
ABOUT THE CONFERENCE
This 3 ½ day conference includes lectures, discussions, and oral/poster presentations focusing on the latest advances in Kawasaki disease. Kawasaki disease is the major cause of acquired childhood heart disease in developed countries. Children who develop significant coronary artery aneurysms as a result of Kawasaki disease have a lifetime increased risk of myocardial ischemia, infarction, and sudden death. The study of Kawasaki disease and its treatment are likely to yield important answers to general questions in cardiovascular health and disease that apply equally to pediatric and adult populations.
The Eleventh International Kawasaki Disease Symposium seeks to address the influence of genetics on disease susceptibility and outcomes, the mechanisms of coronary artery damage following severe acute inflammation, the role of immune modulation and other novel therapies in preventing artery damage, the potential use of serum biomarkers for diagnosis and prognosis, the use of newer imaging techniques to assess abnormalities of the coronary arteries and myocardium, and new therapies regarding anticoagulation and vascular health. Current data regarding the worldwide epidemiology will be highlighted, as well as psychosocial issues, guidelines and nursing practice.
Since the historic first International Kawasaki Disease Symposium in 1984, the international symposium has been held every 3 years in Japan, the United States, or Taiwan, drawing attendees from all continents.
WHO SHOULD ATTEND
The audience will consist of pediatric and adult cardiologists, pediatricians and pediatric subspecialists in immunology, infectious disease, and rheumatology; cardiovascular surgeons; pathologists; basic scientists in genetics, molecular biology, microbiology, and cardiovascular pathophysiology; public health officials from county and state agencies and the Center for Disease Control and Prevention; epidemiologists; and nurses working in pediatric cardiology and public health who have an interest in Kawasaki disease.
- Summarize prevailing hypotheses regarding KD etiology, and discuss emerging research supporting or contradicting these hypotheses.
- Summarize current findings regarding diagnostic and prognostic biomarkers for KD, and their potential significance to clinical practice.
- Summarize the most recent research and clinical findings regarding genetic susceptibility to KD and to KD coronary artery disease.
- Summarize the most recent research and clinical findings regarding IVIG mechanism of action and the efficacy of additional or alternative therapies
- Review evidence regarding the two distinct arterial processes that can lead to myocardial ischemia or infarction.
- Review available imaging modalities for their ability to assess for presence of thrombosis and luminal myofibroblastic proliferation.
- Summarize technical principles and current evidence supporting use of various imaging modalities in determining KD prognosis and optimal long-term follow-up.
- Review evidence regarding the efficacy, safety, and long-term expected outcomes of revascularization options for KD patients.
- Review current understanding, recent findings, and unresolved issues regarding optimization of thromboprophylaxis in KD patients.
Continuing Medical Education Accreditation - Physicians
The American Heart Association is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
The American Heart Association designates this live activity for a maximum of 24.50 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
All persons who develop and/or control educational content in CME/CE activities sponsored by the American Heart Association will disclose to the audience all financial relationships with any commercial supporters of this activity as well as with other commercial interests whose lines of business are related to the CME/CE-certified content of this activity. In addition, presenters will disclose unlabeled/unapproved uses of drugs or devices discussed in their presentations. Such disclosures will be made in writing in course presentation materials.
Continuing Medical Education Accreditation – Physician Assistants
AAPA accepts certificates of participation for educational activities certified for AMA PRA Category 1 Credit™ from organizations accredited by ACCME or a recognized state medical society. Physician assistants may receive a maximum of 24.50 hours of Category I credit for completing this program.
Continuing Medical Education Accreditation – Nurse Practitioners
American Academy of Nurse Practitioners (AANP) accepts AMA PRA Category 1 CreditTM from organizations accredited by the ACCME.
Continuing Education Accreditation - Nurses
The American Heart Association is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation.
The maximum number of hours awarded for this CE activity is 24.50 contact hours.
Steps for Successful Completion
To successfully complete this activity, learners must fully participate in the sessions. In addition, learners must provide feedback that will be used for evaluative and outcomes measurement purposes. Learners’ participation will be verified, and learners will be required to provide evaluative feedback before CME/CE credit can be claimed.
You are strongly encouraged to claim your CME/CE credit within 30 days of the conference. Credit MUST be claimed within 6 months of attendance. CME/CE credit will no longer be available to claim for this activity after August 6, 2015. For customer support please contact our National Engagement Center at 1-888-242-2453 (between 8AM-5PM Central Standard Time) or email firstname.lastname@example.org.
|Photo courtesy of: Hawaii Tourism Authority (HTA)/Joe Solem||Photo courtesy of: Hawaii Tourism Authority (HTA)/Chuck Painter||Photo courtesy of: Hawaii Tourism Japan (HTJ)|